Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles

Open Access

Original Article

J App Pharm Sci. 2016; 6(10): 174-180

Assessment of immunological, haematological and biochemical status after sofosbuvir-based combination therapy in HCV Egyptian patients from Menoufia Province

Hany M. Ibrahim, Mohammed A. Soliman, Ibrahim A. El-Elaimy, Rasha S. El-Hageen.

Chronic hepatitis C virus (HCV) is a serious health problem in Egypt. Although the effectiveness of pegylated interferon (peg-IFN) and ribavirin (RBV) combined therapy, poor response rates and lamentable tolerability were recorded in the chronically HCV infected patients. Sofosbuvir (SOF) target the highly conserved active site of the HCV-specific NS5B polymerase that affect directly the viral replication and has broad genotypic coverage. In the present study we investigated the efficacy of SOF-based combination therapy and its effects on the status of immune cells from chronically infected HCV Egyptian patients. HCV Patients were treated with a combination treatment of SOF, RBV and peg-IFN-α or SOF and RBV for either 12 or 24 weeks. Then biochemical, hematological parameters, immunological phenotyping, PBMCs proliferation and apoptosis were detected pre- and post-treatment. While SOF-based combination therapy improved the liver function, anemia, leucopenia and thrombocytopenia were detected especially after treatment with SOF, RBV and peg-IFN-α-2a. We observed significant reduction in the percentage of CD3+CD4+ and CD3+CD8+ cells post-treatment with either SOF and RBV or SOF, RBV and peg-IFN-α-2a as compared to the baseline. Moreover, SOF-based combination therapy altered the percentage of CD3-CD8+, CD14+ and CD20+ cells. The proliferative capacity of PBMCs was significantly decreased in both regimens, whilst the percentage of apoptotic cells was significantly augmented. SOF-based therapy regimens are efficacious in reducing HCV load in the current study with some adverse effects that include the reduction of the mononuclear cells from the blood periphery by apoptosis.

Key words: sofosbuvir therapy, proliferation, apoptosis, monocytes, lymphocytes

Similar Articles

Generating Monocyte-Derived Endothelial-like Cells for Vascular Regeneration.
Smith RJ, Andreadis ST
Methods in molecular biology (Clifton, N.J.). 2022; 2375(): 13-19

Culturing and Expansion of "Clinical Grade" Neural Stem Cells from the Fetal Human Central Nervous System.
Gelati M, Profico DC, Ferrari D, Vescovi AL
Methods in molecular biology (Clifton, N.J.). 2022; 2389(): 57-66

Inserting new synaptic connections into damaged neural circuits: towards synapse therapy?
Rabinowitch I
Neural regeneration research. 2022; 17(2): 300-301

HOTTIP downregulation reduces neuronal damage and microglial activation in Parkinson's disease cell and mouse models.
Lun P, Ji T, Wan DH, Liu X, Chen XD, Yu S, Sun P
Neural regeneration research. 2022; 17(4): 887-897

Neutrophil-to-lymphocyte ratio in sporadic amyotrophic lateral sclerosis.
Wei QQ, Hou YB, Zhang LY, Ou RW, Cao B, Chen YP, Shang HF
Neural regeneration research. 2022; 17(4): 875-880

Full-text options

Latest Statistics about COVID-19
• pubstat.org

Add your Article(s) to Indexes
• citeindex.org

Covid-19 Trends and Statistics
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.

ScopeMed Web Sites